🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — July 31, 2026

All 8 filings in this digest involve Nasdaq-listed companies receiving deficiency notices for failing to maintain the minimum $1.00 bid price per share over 30 consecutive business days, signaling a concentrated wave of micro-cap distress. The filings cluster around late July 2026, with compliance deadlines in late January 2027, and most companies are exploring reverse stock splits as a potential cure. Notably, bioAffinity Technologies faces an accelerated delisting risk due to a prior reverse split, while DocGo has already secured an additional 180-day grace period. No period-over-period financial trends, insider transactions, or capital allocation data were provided in the enriched filings, limiting quantitative cross-company comparisons. The overarching theme is a sector-wide liquidity and valuation crisis among small-cap biotech and healthcare firms, with no immediate trading halts but significant delisting overhangs. The market implication is heightened volatility and potential forced delistings for companies unable to execute timely reverse splits or attract buying interest.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — July 30, 2026

The regulatory filings from July 24-29, 2026 reveal a concentrated wave of Nasdaq and NYSE listing deficiencies among small-cap and micro-cap companies, signaling heightened regulatory scrutiny and financial fragility in this segment. Four companies—Flux Power Holdings, Curis, Genprex, and Lument Finance Trust—all received or resolved notices related to sub-$1.00 bid prices, a common stress indicator for distressed equities. Genprex's situation is the most acute, having implemented a 1-for-22 reverse stock split and facing an immediate delisting threat under new Nasdaq rules regarding market value of listed securities. Curis narrowly avoided delisting but enters a strict one-year Discretionary Panel Monitor with zero tolerance for future non-compliance. Lument Finance Trust, a mortgage REIT, faces a six-month NYSE cure period, while Flux Power has a 180-day window. The cluster of filings suggests a broader market trend of low-priced stocks struggling to maintain exchange listings, which could trigger forced selling, dilutive reverse splits, or eventual delisting. No period-over-period financial comparisons, insider trading activity, or forward-looking guidance were provided in these filings, limiting quantitative trend analysis but amplifying the binary nature of the risks—compliance or delisting—for each issuer. The materiality is high (8-9/10) for all four, as loss of listing would severely impair liquidity and access to capital for these already vulnerable companies. Investors should view this cluster as a systemic risk signal for the micro-cap ecosystem, where regulatory tightening is accelerating the purge of non-compliant names.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 29, 2026

On July 29, 2026, five US-listed companies disclosed trading suspension risks from Nasdaq and NYSE, all driven by market value and bid price deficiencies. The cluster reveals a severe micro-cap liquidity crisis, with four companies (SCWorx, Foxx Development, Celularity, Loop Industries) facing Nasdaq delisting and one (LiveWire Group) under NYSE scrutiny. No period-over-period revenue or margin data was available in these filings, but the uniform negative sentiment (5/5 filings) and lack of insider buying or capital allocation actions signal a systemic erosion of market confidence. The most critical development is the concentration of compliance deadlines in January 2027, creating a binary catalyst for each stock. The pattern suggests a broader sell-off in low-float, cash-burning small caps, with no company demonstrating a credible turnaround plan.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — July 28, 2026

The two filings in this stream highlight acute regulatory and financial distress within the US-listed equity space, specifically concerning Nasdaq listing compliance. Vestand Inc. (VSTD) has been delisted effective July 27, 2026, due to multiple reporting failures and governance concerns, representing a terminal event for its exchange listing. In contrast, Blink Charging Co. (BLNK) has received a second 180-day extension to cure its bid price deficiency, providing a temporary reprieve but with a high risk of eventual delisting. The overarching theme is a bifurcation between companies that have exhausted their compliance options (Vestand) and those on a final watch (Blink Charging). No period-over-period financial trends or insider activity were available in the enriched data, but the forward-looking data for Blink Charging explicitly flags a potential reverse stock split as a cure, a common but often value-destructive last resort. The market implications are clear: investors should avoid Vestand shares on the OTC market and monitor Blink Charging closely for a potential dilutive event or a final delisting notice in early 2027.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 27, 2026

Three micro-cap companies face acute regulatory and listing crises on US exchanges, signaling a severe liquidity and compliance crunch in the small-cap space. All three filings (AMASS Brands, Nexalin Technology, Picard Medical) report negative sentiment and high materiality (8-9/10), with two facing imminent trading suspension or delisting. Period-over-period data reveals a common pattern: deteriorating equity bases (Picard Medical swung from $3.8M equity to a $(1.4)M deficit QoQ) and sustained market value erosion (AMASS Brands failed the $50M MVLS threshold for 30+ days). No insider buying or positive forward guidance exists across any filing, while capital allocation is absent (no dividends, buybacks, or M&A). The cluster of delisting events within a single week (July 22-24, 2026) suggests a broader regulatory tightening or sector-wide distress. Investors should treat these names as high-risk, with Nexalin's August 4 suspension date being the most immediate catalyst.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 24, 2026

On July 24, 2026, a wave of 16 regulatory filings revealed a surge in trading suspension and delisting risks across US-listed companies, predominantly driven by non-compliance with Nasdaq's $1.00 minimum bid price rule. A staggering 13 of 16 filings involve bid price deficiencies, with several companies receiving their second notice within a year, indicating a systemic failure to maintain share price thresholds. The cluster of filings on a single day suggests a coordinated exchange review cycle, creating a concentrated risk event for investors holding these securities. While most companies have 180-day cure periods, the high recurrence rate and ineligibility for extensions due to prior reverse splits (e.g., FibroBiologics) signal a 'penalty box' dynamic where serial non-compliers face accelerated delisting. The only voluntary delisting (Trinity Capital) and the sole equity-based deficiency (VivoSim Labs) stand as outliers, highlighting that the primary systemic risk is price-driven, not fundamental. The lack of any bullish or positive insider activity across all filings reinforces a uniformly negative sentiment, with management teams scrambling for reverse splits as a last-resort remedy.

16 high priority 16 total filings
· daily

US SEC Trading Suspension Halt Orders — July 23, 2026

On July 22-23, 2026, five US-listed small-cap and micro-cap companies disclosed regulatory listing challenges, highlighting a concentrated round of Nasdaq compliance failures. The filings reveal two distinct themes: immediate trading suspensions/delistings (Nuvve Holding Corp.) and grace-period remediation efforts (Aprea Therapeutics, Fly-E Group, InspireMD, Shore Bancshares). A critical portfolio-level trend is the prevalence of non-compliance with the $1.00 minimum bid price rule (3 of 5 companies), alongside periodic reporting failures (2 of 5). No insider trading activity was reported by any of the companies, suggesting management may be limited in their ability to signal confidence amid regulatory uncertainty. Forward-looking data shows key catalyst dates through January 2027, creating a defined timeline for potential reversals or further downside. The most material development is Nuvve's imminent suspension and move to OTC Pink, representing a near-certain loss of exchange liquidity. The sector-wide pattern suggests increasing regulatory scrutiny on micro-cap compliance with Nasdaq's quantitative and procedural standards.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — July 22, 2026

Both SunPower Inc. and Purple Innovation, Inc. have received Nasdaq notices regarding non-compliance with the minimum $1.00 bid price requirement, highlighting a severe liquidity and market confidence crisis in the solar and consumer goods sectors. SunPower has a 180-day cure period until January 19, 2027, and may seek an additional 180-day extension by moving to the Nasdaq Capital Market, but faces delisting if unable to cure. Purple Innovation received a Hearings Panel decision granting continued listing subject to demonstrating compliance by July 31, 2026, and executed a 1-for-25 reverse stock split effective July 20, 2026, which brought its stock price to $7.12 per share. The period-over-period data shows no revenue or margin trends available, but the insider activity and capital allocation data are absent, suggesting management may be avoiding signaling. The most critical development is the imminent compliance deadline for Purple Innovation (July 31, 2026), which creates a binary event for its listing status. Portfolio-level patterns indicate that both companies are in distressed situations with high delisting risk, and the market should monitor for potential reverse stock splits or further regulatory actions.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 21, 2026

The three filings from July 21, 2026, reveal a concentrated wave of Nasdaq compliance and delisting actions affecting small-cap and micro-cap issuers, signaling heightened regulatory scrutiny on corporate governance, minimum bid price, and foreign issuer disclosures. Notably, two of the three companies face material threats to their listing status, with CN Healthy Food Tech Group Corp. receiving a direct delisting determination tied to CSRC review disclosures, while Cypherpunk Technologies Inc. is in a 180-day cure period for sub-$1.00 bid price non-compliance. Origin Investment Corp I quickly remedied its audit committee deficiency, demonstrating that governance gaps can be resolved swiftly. The aggregate data shows zero insider trading activity across all filings, suggesting management teams are not signaling conviction through personal transactions. No forward-looking guidance, capital allocation changes, or period-over-period financial comparisons were available in these event-driven 8-Ks, limiting trend analysis but amplifying the binary nature of the regulatory risks. The most critical development is CN Healthy Food Tech's July 23 appeal deadline, which will determine whether a full delisting and trading halt extension occurs, with material implications for shareholders of UCFI and UCFIW. The portfolio-level pattern is a clear uptick in Nasdaq enforcement actions against companies with governance gaps, low-priced stocks, and China-based operations facing CSRC scrutiny, creating both risk and potential catalyst-driven opportunities for active traders.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 20, 2026

The July 20, 2026, trading suspension landscape is dominated by a cluster of small-cap companies facing Nasdaq/NYSE non-compliance, with two new filings (Smart Powerr Corp. and SES AI Corp) adding to the existing TEN Holdings situation. The most critical development is Smart Powerr Corp.'s imminent delisting and suspension on July 21, 2026, after failing to appeal a bid price deficiency, which will force a move to the OTCQB market with severe liquidity implications. SES AI Corp has received a similar NYSE notice but has a six-month cure period, providing a more manageable timeline, while TEN Holdings has temporarily resolved its equity deficiency through a $6.6M offering but remains under Nasdaq monitoring. The common thread is a liquidity crisis among micro-cap issuers, with all three companies showing deteriorating financial metrics and no insider buying to signal management confidence. The aggregate data reveals a pattern of regulatory fatigue, where companies exhaust compliance plans and appeal processes before facing final suspension orders.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 17, 2026

On July 17, 2026, four Nasdaq-listed micro-cap companies disclosed imminent delisting or non-compliance risks, signaling a concentrated wave of regulatory enforcement against companies with deteriorating financial health. All four filings carry negative sentiment and high materiality (8-9/10), with common themes of insufficient stockholders' equity, collapsing market values, and sub-$1.00 bid prices. Period-over-period comparisons from the enriched data reveal that Dare Bioscience and Caring Brands both failed the same $2.5M stockholders' equity threshold, while Actuate Therapeutics saw its Market Value of Listed Securities (MVLS) fall below $50M starting June 1, 2026, and Fold Holdings breached the $1.00 minimum bid price for 30 consecutive days. No insider buying or capital allocation actions (dividends, buybacks) were reported across any of the four companies, underscoring severe financial distress and lack of management confidence. The most critical development is Caring Brands' imminent trading suspension deadline of July 24, 2026, if it fails to request a hearing by July 22, 2026—making it the highest-urgency situation. These filings collectively highlight a sector-wide purge of financially weak micro-caps from Nasdaq, with implications for liquidity risk, forced selling, and potential complete loss of equity value for shareholders.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 16, 2026

The three filings in this trading suspensions stream present a mixed landscape for small-cap companies listed on US exchanges. Cycurion, Inc. faces imminent delisting from Nasdaq due to a prolonged bid price deficiency, with no compliance period available after a prior reverse split, creating a high-risk event for shareholders. TG-17, Inc. (Our Bond, Inc.) has received multiple non-compliance notifications for bid price and market value thresholds, but retains a 180-day cure period, offering a potential turnaround window. In contrast, SRx Health Solutions, Inc. (SRX Global Inc.) has resolved its NYSE American deficiency, marking a positive compliance event that removes delisting risk. Period-over-period comparisons are limited as filings are event-driven, but the divergence in outcomes—one delisting, one at risk, one compliant—highlights the binary nature of regulatory compliance for micro-cap equities. No insider trading, capital allocation, or forward-looking guidance data was provided in these filings, limiting trend analysis but emphasizing the criticality of exchange listing status as a catalyst.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 15, 2026

All three filings in this digest center on Nasdaq non-compliance and imminent trading suspensions, creating a concentrated regulatory storm for micro-cap issuers on July 15, 2026. The most critical development is **SPAR Group's** definitive delisting on July 23, 2026, after shareholders rejected a reverse stock split, making its path to appeal the only remaining lifeline—a high-probability suspension event. **SemiLEDs** offers a contrasting narrative: after receiving a stockholders' equity deficiency notice in January 2026, the company submitted a compliance plan, saw equity improve to $3.1 million, and now believes it has regained compliance, though Nasdaq continues to monitor. **Triller Group** faces the tightest deadline, with a Panel exception requiring it to achieve a $1.00 closing bid for 20 consecutive business days by July 30, 2026—a binary catalyst given its history of repeated non-compliance and prior trading halt. Period-over-period data reveals no revenue or margin trends across these filings, as the filings are purely regulatory and non-financial; the core pattern is that all three companies faced equity or bid-price deficiencies, with SPAR Group being the most severe due to shareholder rejection of the cure. The aggregated insider activity is absent, capital allocation data is nil, and forward-looking guidance is limited to regulatory deadlines, underscoring that this stream is purely about listing viability rather than operational performance.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 14, 2026

On July 14, 2026, two US-listed companies announced voluntary transfers of their stock listings between major exchanges, signaling a trend of proactive exchange migration rather than forced delistings. D-Wave Quantum Inc. (QBTS) is moving from the NYSE to Nasdaq, while Trinity Capital Inc. (TRIN) is transferring from Nasdaq to the NYSE and NYSE Texas. Both transfers are voluntary, approved by their boards, and involve no change in ticker symbols for the common stock, though Trinity's notes will see ticker adjustments. The moves are scheduled to take effect around July 27, 2026, with seamless trading continuity. No financial metrics, insider activity, or forward-looking guidance were disclosed in these filings, limiting the depth of quantitative trend analysis. The key takeaway is that both companies are seeking exchange environments they perceive as more advantageous, potentially for visibility, liquidity, or regulatory alignment, without any distress signals.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 13, 2026

Three US-listed micro-cap companies received Nasdaq delisting or suspension notices on July 7-10, 2026, underscoring a severe liquidity and compliance crisis in the small-cap space. Pluri Inc. (PLUR) faces a market value deficiency with a cure period through January 4, 2027, while Actelis Networks (ASNS) has already been suspended and moved to OTCQB, and BNB Plus Corp. (BNBX) will be suspended July 14. All three filings carry negative sentiment and high materiality (9-10/10), with no insider buying, no forward guidance, and no capital allocation actions (dividends/buybacks) reported—indicating distressed balance sheets. The cluster of delistings within a single week suggests heightened regulatory scrutiny on minimum listing standards, particularly for companies with market caps below $35 million. Investors should monitor the OTCQB transition for potential price discovery dislocations and short-squeeze dynamics, while avoiding long exposure until compliance is restored.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 10, 2026

On July 10, 2026, four micro-cap companies filed 8-Ks disclosing Nasdaq non-compliance, creating a concentrated wave of delisting risk in the small-cap space. All four filings are negative in sentiment, with materiality scores ranging from 8/10 to 9/10, signaling a systemic pattern of distress among low-priced equities. GeoVax Labs (GOVX) faces a stockholders' equity deficiency, while NanoVibronix (FEED), Lakeside Holding (LSH), and Mercer International (MERC) all violate the minimum $1.00 bid price rule. Notably, NanoVibronix is ineligible for the standard 180-day cure period due to a prior reverse split, making it the most acute risk. The concentration of these filings on a single day suggests a potential Nasdaq compliance sweep or broader market pressure on micro-cap stocks. No period-over-period financial trends, insider activity, or capital allocation data were available in these filings, limiting quantitative cross-comparison but highlighting the purely regulatory nature of the risk. The key market implication is a potential wave of delistings that could compress valuations across the micro-cap sector and trigger forced selling by index funds.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 09, 2026

All four filings in this digest highlight micro-cap companies facing imminent delisting or trading suspension from US exchanges (NASDAQ and NYSE American), driven by non-compliance with minimum bid price and shareholders' equity requirements. The cluster of events on July 2-9, 2026, signals a potential sector-wide liquidity and valuation crisis among small-cap issuers, with no positive period-over-period trends or insider buying to offset the negative outlook. The most critical development is the immediate delisting risk for Prairie Operating Co. if its stock trades at or below $0.10 for ten consecutive days, representing a binary event. Across the portfolio, all companies are in the 'cure period' with no forward-looking guidance or capital allocation improvements, suggesting a high probability of eventual suspension or delisting. The aggregate market implication is a bearish signal for micro-cap equities, as regulatory enforcement appears to be tightening on chronically non-compliant issuers.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 08, 2026

The single filing in this stream, from Borealis Foods Inc., presents a high-risk delisting scenario on the Nasdaq Capital Market. The company received a deficiency notice for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million, with a 180-day cure period ending December 29, 2026. Critically, Borealis also fails to meet alternative listing standards based on stockholders' equity or net income, significantly narrowing its path to compliance. The negative sentiment and high materiality score (9/10) underscore the existential threat to the company's public listing, with a delisting of common shares automatically triggering the delisting of its warrants (BRLSW). No period-over-period comparisons, insider activity, or forward-looking guidance were provided in the enriched data, limiting trend analysis but amplifying the binary risk of the situation. The lack of any positive catalysts or capital allocation actions (e.g., buybacks) suggests management is in a reactive, rather than proactive, position.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 07, 2026

The single filing for DevvStream Corp. (DEVS) dominates an otherwise silent session for US trading suspensions, delistings, and regulatory halts. The company entered a definitive Securities Purchase Agreement (SPA) for a $6.0M investment, superseding a prior term sheet, with only $1.5M funded to date and the remaining $4.5M due by September 30, 2026. The transaction is contingent on closing a business combination agreement (BCA), creating a binary catalyst with material execution risk. The mixed sentiment and high materiality (8/10) reflect the precarious funding structure and the potential for a dilutive or preferential-share outcome if the BCA fails. No period-over-period comparisons, insider activity, or capital allocation data were available, limiting trend analysis but highlighting a single high-stakes corporate event.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 06, 2026

All three filings (CISO Global, CytoSorbents, Polar Power) involve Nasdaq non-compliance notices, creating a concentrated cluster of delisting risks in the micro-cap and small-cap space. Period-over-period data reveals severe financial deterioration: Polar Power reported only $144,000 in stockholders' equity against a $2.5 million requirement, while CytoSorbents failed the $35 million market value test. CISO Global faces a bid price deficiency. The common deadline of December 28, 2026, for CISO and CytoSorbents suggests a potential wave of delistings in late 2026. Insider activity data is absent across all filings, indicating a lack of management confidence or inability to signal conviction. Capital allocation is non-existent (no dividends, buybacks, or splits), reflecting distressed financial health. The sector theme is a 'Nasdaq Compliance Crisis' for micro-caps, with aggregate equity deficiency of ~$2.36 million and market value shortfall of unknown magnitude. The most critical development is the high probability of at least one delisting by year-end 2026, with Polar Power at highest immediate risk (October 28 deadline).

3 high priority 3 total filings